Study agents | Disease | Dose | No Pts | Clinical trials | Response | Reference |
|---|
Gilteritinib | Relapsed Refractory | 20–450 mg/day | 252 | Phase 1/2 | ORR 40% ORR(FLT+) 52% | [70] |
Gilteritinib | Relapsed Refractory | 20–300 mg/day | 24 | Phase 1 | ORR(FLT3+) 80% ORR(FLT/WT+) 36.4% | [71] |
- ORR overall response rate
